Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides

Annals of the New York Academy of Sciences

Volumn 1082, Issue , 2006, Pages 74-76

  Aartsma Rus, A ^a   Janson, A A M ^a   Heemskerk, J A ^a   De Winter, C L ^a   Van Ommen, G J B ^a   Van Deutekom, J C T ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Antisense oligonucleotides; AONs; Duchenne muscular dystophy; ESE; Exonic splicing enhancer

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ARGININE; SERINE;

COMPUTER MODEL; COMPUTER PROGRAM; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; ENHANCER REGION; EXON; FRAMESHIFT MUTATION; GENE SEQUENCE; HUMAN; HYPOTHESIS; RETROSPECTIVE STUDY; STEREOSPECIFICITY;

EID: 33845667857     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1348.058     Document Type: Conference Paper

References (13)

1. KOENIG, M. et al. 1988. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53: 219-226.
2. YOSHIDA, M. et al. 1990. Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem. (Tokyo) 108: 748-752.
3. HOFFMAN, E.P. et al. 1987. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
4. MONACO, A.P. et al. 1988. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95.
5. AARTSMA-RUS, A. et al. 2002. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12: S71-S77.
6. VAN DEUTEKOM, J.C. et al. 2003. Advances in Duchenne muscular dystrophy gene therapy. Nat. Rev. Genet. 4: 774-783.
7. AARTSMA-RUS, A. et al. 2003. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12: 907-914.
8. AARTSMA-RUS, A. et al. 2004. Antisense-induced multiexon skipping for duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet. 74: 83-92.
9. VAN DEUTEKOM, J.C. et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10: 1547-1554.
10. CARTEGNI, L. et al. 2002. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3: 285-298.
11. CARTEGNI, L. et al. 2003. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31: 3568-3571.
12. FAIRBROTHER, W.G. et al. 2002. Predictive identification of exonic splicing enhancers in human genes. Science 297: 1007-1013.
13. AARTSMA-RUS, A. et al. 2005. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15: 284-297.